سعر ساندوجلوبيولين 6جم 2022

Human normal immunoglobulin 6 g lyophilised powder for intravenous infusion (Sandoglobulin, CSL Behring); 1 vial.

• Replacement therapy in primary immunodeficiency syndromes (congenital agammaglobulinaemia/hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, Wiskott-Aldrich syndrome).CSL Behring (manufacturer labelling site)
• Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; children with congenital AIDS and recurrent infections.CSL Behring (manufacturer labelling site)
• Immunomodulation: idiopathic thrombocytopenic purpura (high bleeding risk or before surgery), Guillain-Barré syndrome, Kawasaki disease.CSL Behring (manufacturer labelling site)

• Common (1–10%) during infusion: headache, nausea, vomiting, diarrhoea, fatigue, malaise, dizziness, tremor, sweating, fever, flushing, allergic reactions, myalgia, arthralgia and moderate back pain. Uncommon: abdominal pain, cyanosis, dyspnoea, chest tightness, hypertension/hypotension, tachycardia. Rare: sudden fall in blood pressure, isolated anaphylactic shock. Very rare: thromboembolic reactions.International label, same formulation · CSL Behring (manufacturer labelling site)

• Hypersensitivity to human immunoglobulins or any component, especially in IgA deficiency with anti-IgA antibodies.International label, same formulation · CSL Behring (manufacturer labelling site)

• Some serious adverse reactions are related to infusion rate; follow the recommended rate and monitor patients closely during the infusion, particularly first-time recipients, patients with hypo-/agammaglobulinaemia and those switching products.International label, same formulation · CSL Behring (manufacturer labelling site)
• Acute renal failure has been reported with IVIG, disproportionately with sucrose-containing products such as this one; in at-risk patients use the lowest concentration and infusion rate and consider stopping if renal function deteriorates. Aseptic meningitis syndrome, haemolysis and thromboembolic events have also been reported.International label, same formulation · CSL Behring (manufacturer labelling site)

• Animal reproduction studies have not been performed and safety in human pregnancy has not been established in controlled trials; long clinical experience with immunoglobulins suggests no harmful effects on pregnancy, fetus or neonate are expected. Use in pregnancy only on medical advice.International label, same formulation · CSL Behring (manufacturer labelling site)
• Immunoglobulins are excreted in breast milk and may contribute to the transfer of protective antibodies to the neonate.International label, same formulation · CSL Behring (manufacturer labelling site)

• Human normal immunoglobulin: Supplies a broad spectrum of IgG antibodies against infectious agents (replacement therapy); in immunomodulatory indications the mechanism is not fully elucidated and includes immunomodulatory effects.